Dr Camerron Crowder
Crowder Lab Research
We support Dr. Crowder’s work to examine phenotypes in MAPK8IP3/JIP3 knockout and patient variant overexpressing zebrafish models of MAPK8IP3-related disorders. Her work aims to identify morphological, behavioral, and cellular consequences of JIP3 loss-of-function and identify therapeutic approaches to treat these disorders. Cammie has developed a large scale drug screening pipeline that uses artificial intelligence and clinician recommendations to prioritize drug candidates for screening of locomotor and behavioral defects in larval and adult zebrafish. (Figure 1)
Figure 1. Zebrafish model development, drug candidate prioritization and screening
About
Dr. Crowder is an Assistant Professor in the Department of Neurobiology and Assistant Director of UAB’s Hugh Kaul Precision Medicine Institute. In her research, Dr. Crowder uses CRISPR-Cas9 gene editing approaches to develop patient-guided zebrafish models of rare neurodevelopmental and neuropsychiatric disorders. Through her work, she aims to describe molecular mechanisms contributing to patient symptoms and complete large-scale drug screens in zebrafish models to identify potential therapeutic options for patients. Prior to her current position, she was awarded an NIH Institutional Research and Academic Career Development Award (IRACDA) and completed her postdoctoral fellow at UAB examining development and rare-human genetic disorders in the labs of Drs. Daniel Gorelick and Matt Might. She received her PhD in 2016 from Oregon State University in Corvallis, OR.
Presented and produced as part of the 2024 Individualizing Medicine Conference in Rochester, MN September 11 and 12, from the Center for Individualized Medicine at Mayo Clinic. Shared with permission by Mayo Clinic.